(Q37413446)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19281637%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

review article

1 reference

title

Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19281637%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

0 references

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19281637%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Paul Hagan

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19281637%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

author name string

D Cioli

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19281637%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

V Southgate

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19281637%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

L Pica-Mattoccia

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19281637%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

S Botros

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19281637%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

G Coles

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19281637%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

L A Tchuem Tchuenté

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19281637%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

A Mbaye

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19281637%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

D Engels

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19281637%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

language of work or name

1 reference

13 March 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19281637%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19281637%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

volume

136

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19281637%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

issue

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19281637%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

page(s)

1825-1835

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19281637%20AND%20SRC:MED&resulttype=core&format=json

on focus list of Wikimedia project

23 January 2020

ScienceSource

0 references

cites work

The WHO dose pole for the administration of praziquantel is also accurate in non-African populations

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Genotoxic activity of praziquantel

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

A blueprint for success: integration of neglected tropical disease control programmes

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Thioredoxin glutathione reductase from Schistosoma mansoni: an essential parasite enzyme and a key drug target

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Specific sites in the Beta Interaction Domain of a schistosome Ca2+ channel beta subunit are key to its role in sensitivity to the anti-schistosomal drug praziquantel

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Creation by mutagenesis of a mammalian Ca(2+) channel beta subunit that confers praziquantel sensitivity to a mammalian Ca(2+) channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

The unacknowledged impact of chronic schistosomiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Asymmetries of poverty: why global burden of disease valuations underestimate the burden of neglected tropical diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Biological characteristics of praziquantel-resistant and -susceptible isolates of Schistosoma mansoni

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Mefloquine--an aminoalcohol with promising antischistosomal properties in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Clinical therapy of schistosomiasis mansoni: the Brazilian contribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Efficacy and side effects of praziquantel treatment in a highly endemic Schistosoma mansoni focus at Lake Albert, Uganda

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Towards control of schistosomiasis in sub-Saharan Africa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Leave children untreated and sustain inequity!

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Voltage-gated calcium channel subunits from platyhelminths: potential role in praziquantel action

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Control of neglected tropical diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Schistosomiasis control: keep taking the tablets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Drugs for the control of parasitic diseases: current status and development in schistosomiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

New initiatives against Africa's worms

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Tolerance of Kenyan Schistosoma mansoni to oxamniquine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

In vitro and in vivo activities of synthetic trioxolanes against major human schistosome species

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Schistosomicidal activity of the antimalarial drug, mefloquine, in Schistosoma mansoni-infected mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Stability and reproductive fitness of Schistosoma mansoni isolates with decreased sensitivity to praziquantel

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Schistosoma mansoni: maturation rate and drug susceptibility of different geographic isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

The global epidemiological situation of schistosomiasis and new approaches to control and research

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Artemisinins and synthetic trioxolanes in the treatment of helminth infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Evidence for an immune-dependent action of praziquantel on Schistosoma mansoni in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Is Schistosomicidal Chemotherapy Sub-curative? Implications for Drug Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Sequence and level of endogenous expression of calcium channel beta subunits in Schistosoma mansoni displaying different susceptibilities to praziquantel

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Interpreting low praziquantel cure rates of Schistosoma mansoni infections in Senegal

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Oral artemether for prevention of Schistosoma mansoni infection: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Will new antischistosomal drugs finally emerge?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Efficacy of praziquantel against Schistosoma mansoni with particular consideration for intensity of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Relative contribution of day-to-day and intra-specimen variation in faecal egg counts of Schistosoma mansoni before and after treatment with praziquantel

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

The efficacy of praziquantel against Schistosoma mansoni infection in Ndombo, northern Senegal

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Antischistosomal drugs: past, present ... and future?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Determination of ED50 values for praziquantel in praziquantel-resistant and -susceptible Schistosoma mansoni isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Projected benefits from integrating NTD programs in sub-Saharan Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Praziquantel binds Schistosoma mansoni adult worm actin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Counterfeit praziquantel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Current status of sensitivity to praziquantel in a focus of potential drug resistance in Egypt

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Parasitological evaluation of curative and subcurative doses of 9-acridanone-hydrazone drugs against Schistosoma mansoni in baboons, and observations on changes in serum levels of anti-egg antibodies detected by ELISA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Effect of praziquantel on the immature stages of Schistosoma haematobium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Schistosomiasis in African infants and preschool children: to treat or not to treat?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Schistosoma haematobium (Egyptian strain): rate of development and effect of praziquantel treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

21 January 2018

Praziquantel resistance

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Oxamniquine cures Schistosoma mansoni infection in a focus in which cure rates with praziquantel are unusually low.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Quantitative high-throughput screen identifies inhibitors of the Schistosoma mansoni redox cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

The influence of sampling effort and the performance of the Kato-Katz technique in diagnosing Schistosoma mansoni and hookworm co-infections in rural Côte d'Ivoire

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Use of triclabendazole for treatment of patients co-infected by Fasciola spp. and S. mansoni in Behera Governorate, Egypt

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Schistosoma mansoni: chemotherapy of infections of different ages

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Praziquantel--quality, dosages and markers of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

An international initiative on praziquantel use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

New policies for using anthelmintics in high risk groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Schistosomiasis mansoni: novel chemotherapy using a cysteine protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Schistosoma mansoni: lack of correlation between praziquantel-induced intra-worm calcium influx and parasite death

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Sex- and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Alterations in cytochrome-c oxidase expression between praziquantel-resistant and susceptible strains of Schistosoma mansoni.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Central effects in man of the novel schistosomicidal benzodiazepine meclonazepam

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

Rapid mapping of schistosomiasis and other neglected tropical diseases in the context of integrated control programmes in Africa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

7 January 2021

Alteration of Schistosoma mansoni malate dehydrogenase isoenzymes on passage in the laboratory

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

7 January 2021

Evidence for host-induced selection in Schistosoma mansoni

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

7 January 2021

Susceptibility to chemotherapeutic agents of strains of Schistosoma mansoni isolated from treated and untreated patients

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

7 January 2021

Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni.

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

7 January 2021

Randomly amplified polymorphic DNA (RAPD) polymerase chain reaction assay for identification of Schistosoma mansoni strains sensitive or tolerant to anti-schistosomal drugs

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

7 January 2021

Is actin the praziquantel receptor?

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

7 January 2021

Cytochalasin D abolishes the schistosomicidal activity of praziquantel

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

7 January 2021

Increased exposure of parasite antigens at the surface of adult male Schistosoma mansoni exposed to praziquantel in vitro

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

7 January 2021

The effect of single dose versus two doses of praziquantel on Schistosoma haematobium infection and pathology among school-aged children in Mali

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

7 January 2021

https://api.crossref.org/works/10.1017%2FS0031182009000493

1 reference

7 January 2021

A high-performance liquid chromatography and nuclear magnetic resonance spectroscopy-based analysis of commercially available praziquantel tablets

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

7 January 2021

Triclabendazole and its two main metabolites lack activity against Schistosoma mansoni in the mouse model.

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

7 January 2021

Praziquantel and the benzodiazepine Ro 11-3128 do not compete for the same binding sites in schistosomes

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

7 January 2021

Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific.

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

7 January 2021

Schistosomiasis in the Senegal River Basin: before and after the construction of the dams at Diama, Senegal and Manantali, Mali and future prospects

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

7 January 2021

Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel.

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

7 January 2021

Lack of evidence for an antischistosomal activity of myrrh in experimental animals.

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

7 January 2021

Therapeutic evaluation of two different dose regimens of praziquantel in a recent Schistosoma mansoni focus in Northern Senegal

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

7 January 2021

Efficacy of praziquantel against Schistosoma mansoni in northern Senegal

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

7 January 2021

The schistosome enzyme that activates oxamniquine has the characteristics of a sulfotransferase

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

7 January 2021

A safe, effective, herbal antischistosomal therapy derived from myrrh.

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

7 January 2021

Therapeutic failure of praziquantel in the treatment of Schistosoma haematobium infection in Brazilians returning from Africa

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

7 January 2021

Genetic analysis of decreased praziquantel sensitivity in a laboratory strain of Schistosoma mansoni.

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

7 January 2021

Studies on schistosomiasis in western Kenya: II. Efficacy of praziquantel for treatment of schistosomiasis in persons coinfected with human immunodeficiency virus-1.

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

7 January 2021

Comparison of the therapeutic efficacy and side effects of a single dose of levo-praziquantel with mixed isomer praziquantel in 278 cases of schistosomiasis japonica

1 reference

https://api.crossref.org/works/10.1017%2FS0031182009000493

7 January 2021

10.1017/S0031182009000493

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19281637%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference